HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥COCOON: Improving Prevention of Moderate to Severe Dermatologic Adverse Events in EGFR-Mutant Advanced NSCLC Treated With First-Line (1L) Subcutaneous (SC) Amivantamab + Lazertinib: First Results From a New COCOON Cohort 🎙️ @cbcbc1971 🔢2700RO 🎯Optimized Dermatologic Management With Zinc Supplementation 🎯Grade≥2 DAEIs by Wk 12 in 34% 🎯Scalp 5%, Paronychia 18%; Dose Reductions 11%, Discontinuations 3% ☑️NCT06120140 🔗 https://t.co/E2MIRGnkpb @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
热度 8 · 7 赞 · 0 回复 · 1 转发
会议摘要
NCT06120140NCT06120140按 - **标题 / Title：** Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib 对上
- **标题 / Title：** Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib读摘要原文 →来源：HHorinouchi · x.com